WE’RE MOVING TOWARD PRECISION MEDICINE IN PSYCHIATRY.
WHAT WE DO
Clinical Implementation
Providing recommendations to physician on optimizing antidepressant and antipsychotic treatment using genetic testing
Pharmacogenomics
Exploring the effects of genetic variation on the response to psychotropic medications and side effects, such as antipsychotic-induced weight gain
Machine Learning
Developing predictive models for treatment response using massive multi-omic and clinical data
Gut Microbiome
Conducting multi-phase preclinical and clinical studies in patients diagnosed with schizophrenia to evaluate the impact of gut bacteria and prebiotics
THE TEAM LEAD
Dr. Daniel Mueller, MD PhD
Dr. Mueller is Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications. Dr. Mueller is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with international organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the International Society of Psychiatric Genetics (ISPG) and the Pharmacogenetics Research Network (PGRN).
RECENT TALKS
Precision Prescirbing in Psychiatry using Pharmacogenomics
March 2024
ACMG Annual Clinical Genetics Meeting
Pharmacogenetics for Psychiatric Disorders: From bench to bedside
RECENT PUBLICATIONS
July 2025
Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report
Magarbeh L, Elsheikh SSM, Islam F, Marshe VS, Men X, Tavakoli E, Kronenbuerger M, Kloiber S, Frey BN, Milev R, Soares CN, Parikh SV, Placenza F, Hassel S, Taylor VH, Leri F, Blier P, Uher R, Farzan F, Lam RW, Turecki G, Foster JA, Rotzinger S, Kennedy SH, Müller DJ.
Nov 2024
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study
Elsheikh SSM, Marshe VS, Men X, Islam F, Gonçalves VF, Paré G, Felsky D, Kennedy JL, Mulsant BH, Reynolds CF 3rd, Lenze EJ, Müller DJ.
May 2024
CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
Men X, Taylor ZL, Marshe VS, Blumberger DM, Karp JF, Kennedy JL, Lenze EJ, Reynolds CF 3rd, Stefan C, Mulsant BH, Ramsey LB & Müller DJ.
Mar 2024
Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study
Islam F, Magarbeh L, Elsheikh SSM, Kloiber S, Espinola CW, Bhat V, Frey BN, Milev R, Soares CN, Parikh SV, Placenza F, Hassel S, Taylor VH, Leri F, Blier P, Uher R, Farzan F, Lam RW, Turecki G, Foster JA, Rotzinger S, Kennedy SH & Müller DJ.
AFFILIATES & FUNDING
Pharmacogenetics Research Clinic,
Centre for Addiction and Mental Health
250 College Street
Toronto ON
CANADA M5T 1R8